Cytokine and inflammatory mediator pathways

Cytokine and inflammatory mediator pathways represent the complex network of signaling proteins and intracellular cascades that coordinate the body's immune and inflammatory responses. These pathways are initiated by the binding of cytokines—including interleukins, interferons, and tumor necrosis factors—to specific cell-surface receptors, which then activate downstream mediators such as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and nuclear factor-kappa B (NF-κB) pathways (Source: StatPearls, "Cytokines", 2023). While essential for host defense and tissue repair, the dysregulation or chronic activation of these pathways is a central driver in the pathogenesis of autoimmune disorders, chronic inflammatory diseases, and "cytokine storms" seen in severe infections (Source: Nature Reviews Immunology, "Cytokine targets in inflammation", 2019). Therapeutic strategies targeting these pathways include monoclonal antibodies that neutralize specific cytokines, decoy receptors, and small-molecule inhibitors that block intracellular signaling enzymes. However, because these pathways are integral to normal immune surveillance, their therapeutic inhibition often leads to significant safety concerns, particularly an increased risk of serious opportunistic infections and potential malignancies (Source: NIH, "Inflammation", 2024).

Other names

Inflammatory signaling cascadesCytokine signaling networkPro-inflammatory pathwaysCytokine-cytokine receptor interaction

Drugs targeting these pathways typically act by neutralizing circulating cytokine ligands, blocking cell-surface receptors to prevent ligand binding, or inhibiting intracellular signaling enzymes such as Janus kinases (JAKs) to prevent the phosphorylation of STAT proteins and subsequent transcription of pro-inflammatory genes.